Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19851975 | 0.91 | CYP4F2 (0.36) | MMP8CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL6893080 | 0.86 | MMP8 (0.37) | MMP8CYP4F2CYP4A11ABCB1ALDH1A1 | |
| SCHEMBL18924865 | 0.84 | MMP8 (0.33) | MMP8 | |
| SCHEMBL20260579 | 0.84 | MMP8 (0.33) | MMP8 | |
| SCHEMBL18924773 | 0.84 | MMP8 (0.33) | MMP8ALDH1A1 | |
| SCHEMBL6895578 | 0.83 | CYP4F2 (0.40) | MMP8CYP4F2CYP4A11ABCB1ALDH1A1 | |
| SCHEMBL14873510 | 0.83 | MMP8 (0.37) | MMP8CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL6895564 | 0.82 | PRKCA (0.42) | MMP8CYP4F2CYP4A11ABCB1ALDH1A1 | |
| SCHEMBL6895404 | 0.81 | CYP4F2 (0.45) | MMP8CYP4F2CYP4A11ABCB1 | |
| SCHEMBL20381855 | 0.80 | FAAH (0.36) | CYP4F2CYP4A11ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | MMP8 3384/4885CYP4F2 503/4885CYP4A11 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.